Beyond the evidence: why multistakeholder cooperation will determine whether cancer genomics reaches patients.
The Lancet Oncology · · Journal Article
Beyond the evidence: why multistakeholder cooperation will determine whether cancer genomics reaches patients.
Normanno
The AI brief for this paper is being written. Open it in JClub to read the paper with the brief as soon as it lands.
Read the brief in JClub →Related in JClub
Cancer Cell · · Journal Article
Spatial multi-omics reveals that liver micrometastases in colorectal cancer originate early and exhibit dormancy, with a six-gene signature linked to disease recurrence and therapy resistance.
- Open access
- 4 cites
- Lancet OncolJClub
The Lancet Oncology · · Review
Access to cancer genomics and precision oncology remains profoundly unequal worldwide, limiting benefits for millions of patients and hindering research progress.
- 10 cites
- Cancer ResJClub
Cancer Research · · Conference Proceedings
Multiomics, computational biology, and ancestry-specific genomics are transforming proactive cancer care with new insights into tumor biology and targeted therapies.
- 1 opens in JClub